Details of the Drug Combination

General Information of Drug Combination (ID: DC4FEFD)

Drug Combination Name
PMID25656651-Compound-7 Paclitaxel
Indication
Disease Entry Status REF
Breast Cancer Phase 1 [1]
Component Drugs PMID25656651-Compound-7   DMK3TMD Paclitaxel   DMLB81S
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
PMID25656651-Compound-7 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Fusion protein Bcr-Abl (Bcr-Abl) TTS7G69 BCR_HUMAN-ABL1_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
Indication(s) of Paclitaxel
Disease Entry ICD 11 Status REF
Breast carcinoma N.A. Approved [2]
Cutaneous melanoma 2C30 Approved [2]
Cutaneous squamous cell carcinoma 2C30 Approved [2]
Epithelial ovarian cancer 2B5D Approved [2]
Extragonadal germ cell tumor N.A. Approved [2]
Fallopian tube neoplasm N.A. Approved [2]
Gastroesophageal junction adenocarcinoma 2B71 Approved [2]
Inflammatory breast cancer 2C62 Approved [2]
Kaposi sarcoma 2B57 Approved [2]
Lung adenocarcinoma N.A. Approved [2]
Lung cancer 2C25.0 Approved [2]
Non-small-cell lung cancer 2C25.Y Approved [2]
Ocular hypertension 9C61.01 Approved [2]
Ovarian neoplasm N.A. Approved [2]
Ovarian serous cystadenocarcinoma N.A. Approved [2]
Pain MG30-MG3Z Approved [2]
Pancreatic ductal carcinoma 2C10.0 Approved [2]
Primary peritoneal carcinoma N.A. Approved [2]
Testicular germ cell tumor N.A. Approved [2]
Urethral cancer 2C93 Approved [2]
Lung large cell carcinoma N.A. Investigative [2]
Paclitaxel Interacts with 11 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [17]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [18]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [19]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [20]
Organic anion transporter 2 (SLC22A7) DT0OC1Q S22A7_HUMAN Substrate [21]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [22]
Multidrug resistance-associated protein 3 (ABCC3) DTQ3ZHF MRP3_HUMAN Substrate [23]
Multidrug resistance protein 3 (ABCB4) DTZRMK5 MDR3_HUMAN Substrate [24]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [25]
TAP-like protein (ABCB9) DT68UV2 ABCB9_HUMAN Substrate [26]
Multidrug resistance-associated protein 7 (ABCC10) DTPS120 MRP7_HUMAN Substrate [27]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 DTP(s)
Paclitaxel Interacts with 338 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Decreases Expression [28]
ATP-binding cassette sub-family C member 10 (ABCC10) OT2JRWWJ MRP7_HUMAN Increases Expression [29]
ATP-binding cassette sub-family C member 3 (ABCC3) OTC3IJV4 MRP3_HUMAN Increases Expression [29]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Decreases Response To Substance [30]
Phosphatidylcholine translocator ABCB4 (ABCB4) OTE6PY83 MDR3_HUMAN Decreases Response To Substance [31]
Solute carrier family 22 member 7 (SLC22A7) OTKTNH1W S22A7_HUMAN Increases Transport [21]
Cyclin-dependent kinase 20 (CDK20) OTOLNN68 CDK20_HUMAN Decreases Expression [32]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Activity [33]
TNF receptor-associated factor 1 (TRAF1) OTTLM5RU TRAF1_HUMAN Decreases Expression [32]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Decreases Expression [34]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Decreases Expression [34]
Bcl2-associated agonist of cell death (BAD) OT63ERYM BAD_HUMAN Increases Expression [9]
Poly polymerase 1 (PARP1) OTIESHK4 PARP1_ARATH Increases ADR [4]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Activity [35]
Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B) OTUYHB84 MLP3B_HUMAN Increases Expression [33]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [36]
Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A) OTBPCU2O TR10A_HUMAN Increases Expression [37]
Sulfhydryl oxidase 1 (QSOX1) OT4ZPK4P QSOX1_HUMAN Decreases Expression [6]
Serine/threonine-protein kinase PLK4 (PLK4) OTV8KZDZ PLK4_HUMAN Decreases Expression [6]
TNF receptor-associated factor 5 (TRAF5) OTSBTLO0 TRAF5_HUMAN Decreases Expression [6]
Myc box-dependent-interacting protein 1 (BIN1) OTK8O0X8 BIN1_HUMAN Increases Expression [38]
Nucleoside diphosphate kinase, mitochondrial (NME4) OT2JTT42 NDKM_HUMAN Decreases Expression [7]
Potassium channel subfamily K member 3 (KCNK3) OTWMAV6G KCNK3_HUMAN Increases Expression [7]
Apoptotic protease-activating factor 1 (APAF1) OTJWIVY0 APAF_HUMAN Increases Expression [34]
Acyl-coenzyme A thioesterase 8 (ACOT8) OTHY684G ACOT8_HUMAN Decreases Expression [39]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [37]
Mitogen-activated protein kinase 13 (MAPK13) OT0W9GE7 MK13_HUMAN Increases Expression [7]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [40]
High affinity copper uptake protein 1 (SLC31A1) OTXLRTUB COPT1_HUMAN Increases Expression [29]
ATP-binding cassette sub-family C member 5 (ABCC5) OT34G4US MRP5_HUMAN Increases Expression [29]
Kunitz-type protease inhibitor 2 (SPINT2) OTQV7BKQ SPIT2_HUMAN Decreases Expression [38]
Adenylate cyclase type 6 (ADCY6) OTFOY4WW ADCY6_HUMAN Decreases Expression [6]
Protein regulator of cytokinesis 1 (PRC1) OTHD0XS0 PRC1_HUMAN Increases Expression [41]
Mitotic checkpoint protein BUB3 (BUB3) OTU91HAU BUB3_HUMAN Increases Expression [7]
Phospholipid phosphatase 2 (PLPP2) OT0BQAXX PLPP2_HUMAN Decreases Expression [38]
Myelin protein zero-like protein 2 (MPZL2) OTKFNDUI MPZL2_HUMAN Decreases Expression [38]
Dual specificity protein phosphatase CDC14B (CDC14B) OTAESVOZ CC14B_HUMAN Decreases Expression [32]
Hyaluronan mediated motility receptor (HMMR) OT4M0JTZ HMMR_HUMAN Decreases Expression [7]
Serine/threonine-protein kinase/endoribonuclease IRE1 (ERN1) OTY9R6FZ ERN1_HUMAN Increases Expression [42]
Death effector domain-containing protein (DEDD) OTIL349E DEDD_HUMAN Decreases Expression [6]
Serine hydrolase RBBP9 (RBBP9) OT0Z04L6 RBBP9_HUMAN Decreases Expression [6]
Tumor necrosis factor ligand superfamily member 13 (TNFSF13) OT90OWIO TNF13_HUMAN Increases Expression [32]
ATP-dependent Clp protease ATP-binding subunit clpX-like, mitochondrial (CLPX) OTIT4JL0 CLPX_HUMAN Increases Expression [7]
Apoptosis-inducing factor 1, mitochondrial (AIFM1) OTKPWB7Q AIFM1_HUMAN Increases Expression [32]
Securin (PTTG1) OTIMYS4W PTTG1_HUMAN Affects Expression [43]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [7]
Collagen alpha-1(I) chain (COL1A1) OTI31178 CO1A1_HUMAN Increases Expression [38]
Collagen alpha-1(IV) chain (COL4A1) OTL6D1YE CO4A1_HUMAN Increases Expression [38]
RAF proto-oncogene serine/threonine-protein kinase (RAF1) OT51LSFO RAF1_HUMAN Increases Phosphorylation [44]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Increases Expression [45]
Thy-1 membrane glycoprotein (THY1) OTVONVTB THY1_HUMAN Increases Expression [38]
Apolipoprotein D (APOD) OTT77XW8 APOD_HUMAN Increases Expression [38]
Propionyl-CoA carboxylase alpha chain, mitochondrial (PCCA) OTWJTCRK PCCA_HUMAN Decreases Expression [7]
Eukaryotic translation initiation factor 2 subunit 1 (EIF2S1) OTM0GDTP IF2A_HUMAN Increases Phosphorylation [42]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Phosphorylation [46]
Transcription factor AP-2-alpha (TFAP2A) OTMYT3NK AP2A_HUMAN Increases Expression [47]
Keratin, type I cytoskeletal 18 (KRT18) OTVLQFIP K1C18_HUMAN Increases Expression [48]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Increases Phosphorylation [49]
Prosaposin (PSAP) OTUOEKY7 SAP_HUMAN Decreases Expression [6]
Collagen alpha-2(IV) chain (COL4A2) OTJK1LKN CO4A2_HUMAN Increases Expression [38]
SPARC (SPARC) OTPN90H0 SPRC_HUMAN Increases Expression [38]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [50]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [51]
Collagen alpha-1(VI) chain (COL6A1) OTYKSCOB CO6A1_HUMAN Increases Expression [38]
Collagen alpha-2(VI) chain (COL6A2) OTQC6PPO CO6A2_HUMAN Increases Expression [38]
ADP/ATP translocase 1 (SLC25A4) OTKYLK2J ADT1_HUMAN Decreases Expression [6]
Elongation factor 2 (EEF2) OTZ7SZ39 EF2_HUMAN Decreases Expression [6]
Glial fibrillary acidic protein (GFAP) OTQ01ZAS GFAP_HUMAN Increases Expression [52]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [53]
Epithelial cell adhesion molecule (EPCAM) OTHBZK5X EPCAM_HUMAN Decreases Expression [38]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) OTRFV19J ATF4_HUMAN Increases Expression [42]
DNA ligase 1 (LIG1) OTEEQS43 DNLI1_HUMAN Decreases Expression [6]
Ephrin-A1 (EFNA1) OTU2NUA2 EFNA1_HUMAN Decreases Expression [38]
Tumor necrosis factor alpha-induced protein 3 (TNFAIP3) OTVLI4DD TNAP3_HUMAN Increases Expression [32]
Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) OTBZKX4P ROA2_HUMAN Decreases Expression [6]
Insulin-like growth factor-binding protein 4 (IGFBP4) OT2HZRBD IBP4_HUMAN Increases Expression [38]
Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2) OTIN6G20 CPT2_HUMAN Decreases Expression [39]
Signal transducer CD24 (CD24) OT7CODJ4 CD24_HUMAN Decreases Expression [38]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Decreases Expression [54]
Protein S100-P (S100P) OTJCXNJG S100P_HUMAN Decreases Expression [38]
Protein S100-A4 (S100A4) OTLRGFSQ S10A4_HUMAN Increases Expression [38]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Phosphorylation [10]
Long-chain specific acyl-CoA dehydrogenase, mitochondrial (ACADL) OTP7Y0UF ACADL_HUMAN Decreases Expression [7]
M-phase inducer phosphatase 3 (CDC25C) OTPQI71S MPIP3_HUMAN Decreases Expression [32]
Adenylosuccinate synthetase isozyme 2 (ADSS2) OTW26XXB PURA2_HUMAN Decreases Expression [7]
Heterogeneous nuclear ribonucleoprotein H (HNRNPH1) OTFRWOLM HNRH1_HUMAN Decreases Expression [6]
Stress-induced-phosphoprotein 1 (STIP1) OT7TXLOX STIP1_HUMAN Increases Expression [7]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Decreases Phosphorylation [10]
Tyrosine-protein phosphatase non-receptor type 7 (PTPN7) OTXYSIIV PTN7_HUMAN Increases Expression [7]
Fibrillin-1 (FBN1) OTYCJT63 FBN1_HUMAN Increases Expression [38]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Increases Expression [42]
Breast cancer type 1 susceptibility protein (BRCA1) OT5BN6VH BRCA1_HUMAN Decreases Expression [55]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Decreases Expression [56]
Collagen alpha-1(XVIII) chain (COL18A1) OTJFUH6O COIA1_HUMAN Increases Expression [38]
Replication factor C subunit 5 (RFC5) OTAD79RT RFC5_HUMAN Decreases Expression [7]
Mitogen-activated protein kinase 8 (MAPK8) OTEREYS5 MK08_HUMAN Increases Activity [57]
Mitogen-activated protein kinase 9 (MAPK9) OTCEVJ9E MK09_HUMAN Increases Expression [58]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Increases Expression [59]
Isocitrate dehydrogenase , mitochondrial (IDH2) OTTQA4PB IDHP_HUMAN Decreases Expression [6]
4-trimethylaminobutyraldehyde dehydrogenase (ALDH9A1) OTNWHUJ1 AL9A1_HUMAN Increases Expression [7]
Centromere protein F (CENPF) OT7AG0SW CENPF_HUMAN Increases Expression [60]
NADH dehydrogenase flavoprotein 1, mitochondrial (NDUFV1) OTEVK4WW NDUV1_HUMAN Decreases Expression [6]
Carnitine O-palmitoyltransferase 1, liver isoform (CPT1A) OTI862QH CPT1A_HUMAN Decreases Expression [39]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10) OT4PXBTA TNF10_HUMAN Increases Expression [7]
Dual specificity protein phosphatase 3 (DUSP3) OTPJX9B4 DUS3_HUMAN Decreases Expression [6]
Cyclin-H (CCNH) OTKDU3SR CCNH_HUMAN Increases Expression [7]
Activated RNA polymerase II transcriptional coactivator p15 (SUB1) OTK71JYU TCP4_HUMAN Decreases Expression [7]
Epithelial membrane protein 3 (EMP3) OTODMJ1D EMP3_HUMAN Increases Expression [38]
Cadherin-11 (CDH11) OTIZKPTF CAD11_HUMAN Increases Expression [38]
Tumor protein D52 (TPD52) OTPKSK43 TPD52_HUMAN Decreases Expression [38]
BH3-interacting domain death agonist (BID) OTOSHSHU BID_HUMAN Increases Cleavage [52]
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN) OTOWDUNT PTEN_HUMAN Increases Activity [61]
Eukaryotic initiation factor 4A-I (EIF4A1) OTMTBX6N IF4A1_HUMAN Decreases Expression [7]
Actin, aortic smooth muscle (ACTA2) OTEDLG8E ACTA_HUMAN Increases Expression [62]
SH3 domain-binding protein 2 (SH3BP2) OT90JNBS 3BP2_HUMAN Decreases Expression [7]
General transcription factor II-I (GTF2I) OTUYL1TQ GTF2I_HUMAN Decreases Expression [6]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Increases Expression [7]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Decreases Expression [63]
Copper-transporting ATPase 1 (ATP7A) OTMR3GXP ATP7A_HUMAN Increases Expression [29]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [32]
Heat shock protein beta-3 (HSPB3) OTE67YM5 HSPB3_HUMAN Increases Expression [7]
Lymphocyte cytosolic protein 2 (LCP2) OT57KE22 LCP2_HUMAN Increases Expression [7]
FAS-associated death domain protein (FADD) OTV7GFHH FADD_HUMAN Increases Expression [32]
Mitogen-activated protein kinase kinase kinase 1 (MAP3K1) OTS3FVTY M3K1_HUMAN Increases Cleavage [57]
MAGUK p55 subfamily member 3 (MPP3) OTNOL0HA MPP3_HUMAN Increases Expression [7]
Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2) OTTUU92F ENPP2_HUMAN Increases Expression [38]
Protein-tyrosine kinase 6 (PTK6) OT7NWIQ0 PTK6_HUMAN Increases Expression [6]
Protein BTG3 (BTG3) OT9ANHVT BTG3_HUMAN Increases Expression [7]
Src substrate cortactin (CTTN) OTJRG4ES SRC8_HUMAN Decreases Expression [7]
Caprin-1 (CAPRIN1) OTEJAMS3 CAPR1_HUMAN Decreases Expression [32]
Procollagen C-endopeptidase enhancer 1 (PCOLCE) OTJXOAN4 PCOC1_HUMAN Increases Expression [38]
Transcription factor E2F5 (E2F5) OT1XWING E2F5_HUMAN Increases Expression [6]
Microtubule-associated protein RP/EB family member 1 (MAPRE1) OTCVQD60 MARE1_HUMAN Decreases Localization [64]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Increases Expression [9]
Transcriptional regulator QRICH1 (QRICH1) OTPVAX04 QRIC1_HUMAN Increases Phosphorylation [65]
Parafibromin (CDC73) OT6JASZ1 CDC73_HUMAN Decreases Expression [32]
Inactive caspase-12 (CASP12) OTY2W6FG CASPC_HUMAN Decreases Expression [63]
Heme A synthase COX15 (COX15) OTUIYHIW COX15_HUMAN Decreases Expression [6]
Ribonucleoside-diphosphate reductase subunit M2 B (RRM2B) OTE8GBUR RIR2B_HUMAN Increases Expression [66]
Cell division cycle and apoptosis regulator protein 1 (CCAR1) OTUXLQZZ CCAR1_HUMAN Increases Expression [32]
Abnormal spindle-like microcephaly-associated protein (ASPM) OTKXQMNA ASPM_HUMAN Increases Expression [41]
Phospholipid-transporting ATPase ABCA7 (ABCA7) OT51S50X ABCA7_HUMAN Increases Expression [29]
Centromere protein S (CENPS) OTZ4J391 CENPS_HUMAN Increases Expression [32]
NAD-dependent protein deacylase sirtuin-6 (SIRT6) OTF755ZO SIR6_HUMAN Decreases Expression [42]
Cholesterol transporter ABCA5 (ABCA5) OT4B9D92 ABCA5_HUMAN Increases Expression [29]
MAP kinase-activating death domain protein (MADD) OTUFYVGG MADD_HUMAN Decreases Expression [6]
Mucin-16 (MUC16) OTHPPE67 MUC16_HUMAN Decreases Expression [67]
Rap guanine nucleotide exchange factor 5 (RAPGEF5) OT53VS75 RPGF5_HUMAN Increases Expression [7]
Transcription factor AP-2 gamma (TFAP2C) OTUDIW05 AP2C_HUMAN Decreases Expression [38]
Engulfment and cell motility protein 3 (ELMO3) OTQHO9VM ELMO3_HUMAN Increases Expression [7]
p53 apoptosis effector related to PMP-22 (PERP) OTP0YL53 PERP_HUMAN Increases Expression [32]
Bcl-2-binding component 3, isoforms 3/4 (BBC3) OTUAXDAY BBC3B_HUMAN Increases Expression [68]
Cell division cycle 5-like protein (CDC5L) OTTPFUU5 CDC5L_HUMAN Decreases Expression [32]
M-phase phosphoprotein 6 (MPHOSPH6) OT6E2S48 MPH6_HUMAN Decreases Expression [7]
Heterogeneous nuclear ribonucleoprotein A/B (HNRNPAB) OTUKPFOK ROAA_HUMAN Decreases Expression [6]
Transmembrane protein 243 (TMEM243) OT8NQ79G TM243_HUMAN Increases Expression [69]
Cell division cycle-associated protein 7 (CDCA7) OT12HDZY CDCA7_HUMAN Decreases Expression [32]
Transmembrane gamma-carboxyglutamic acid protein 4 (PRRG4) OT2SZQI7 TMG4_HUMAN Decreases Expression [38]
TRIO and F-actin-binding protein (TRIOBP) OTGB5WHC TARA_HUMAN Increases Expression [7]
Bridging integrator 3 (BIN3) OTMIWWDW BIN3_HUMAN Decreases Expression [7]
Diablo IAP-binding mitochondrial protein (DIABLO) OTHJ9MCZ DBLOH_HUMAN Increases Expression [63]
NAD-dependent protein deacetylase sirtuin-7 (SIRT7) OT5M4OT4 SIR7_HUMAN Decreases Expression [42]
Olfactomedin-like protein 3 (OLFML3) OTDN45FN OLFL3_HUMAN Increases Expression [38]
G2 and S phase-expressed protein 1 (GTSE1) OTPP742Z GTSE1_HUMAN Increases Expression [7]
ETS homologous factor (EHF) OTY6TPWD EHF_HUMAN Decreases Expression [38]
Programmed cell death 1 ligand 1 (CD274) OTJ0VFDL PD1L1_HUMAN Increases Expression [70]
DNA polymerase kappa (POLK) OTKZ38JH POLK_HUMAN Decreases Expression [6]
Protein Hook homolog 1 (HOOK1) OTTTKV7V HOOK1_HUMAN Decreases Expression [38]
PR domain zinc finger protein 4 (PRDM4) OTD9PAZJ PRDM4_HUMAN Decreases Expression [7]
F-box only protein 5 (FBXO5) OTTR957W FBX5_HUMAN Affects Expression [43]
Neurabin-1 (PPP1R9A) OTJL2TOC NEB1_HUMAN Decreases Expression [6]
Microtubule-associated protein RP/EB family member 3 (MAPRE3) OTSCLETV MARE3_HUMAN Affects Localization [64]
Cyclin-D-binding Myb-like transcription factor 1 (DMTF1) OTDKO9OO DMTF1_HUMAN Decreases Expression [6]
RuvB-like 2 (RUVBL2) OTGWJ4T4 RUVB2_HUMAN Decreases Expression [7]
C-type lectin domain family 11 member A (CLEC11A) OT9KBH7C CLC11_HUMAN Increases Expression [38]
Tumor necrosis factor ligand superfamily member 13B (TNFSF13B) OTND26XR TN13B_HUMAN Increases Expression [32]
Cyclic AMP-dependent transcription factor ATF-5 (ATF5) OT03QCLM ATF5_HUMAN Decreases Expression [6]
Protein-arginine deiminase type-2 (PADI2) OTT40K94 PADI2_HUMAN Decreases Expression [7]
Mitochondrial import inner membrane translocase subunit Tim22 (TIMM22) OTJMHX1V TIM22_HUMAN Increases Expression [7]
Small ribosomal subunit protein mS40 (MRPS18B) OT1K9PFX RT18B_HUMAN Decreases Expression [7]
Transforming acidic coiled-coil-containing protein 3 (TACC3) OTRNEZTA TACC3_HUMAN Decreases Expression [7]
Sorting nexin-10 (SNX10) OT05B7BT SNX10_HUMAN Affects Response To Substance [12]
Superoxide dismutase (SOD2) OT08HOR5 Q4ZJI1_HUMAN Increases ADR [4]
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3) OT0DZGY4 E2AK3_HUMAN Affects Response To Substance [12]
Interleukin-17 receptor B (IL17RB) OT0KDNSF I17RB_HUMAN Decreases Response To Substance [71]
Oxysterol-binding protein-related protein 10 (OSBPL10) OT0TFMBE OSB10_HUMAN Affects Response To Substance [12]
NADH dehydrogenase 1 alpha subcomplex subunit 13 (NDUFA13) OT0UOKIT NDUAD_HUMAN Affects Response To Substance [12]
Tripartite motif-containing protein 2 (TRIM2) OT0V1YVC TRIM2_HUMAN Affects Response To Substance [12]
Condensin complex subunit 3 (NCAPG) OT1AI9EO CND3_HUMAN Affects Response To Substance [12]
Integrin beta-5 (ITGB5) OT21MF51 ITB5_HUMAN Decreases Response To Substance [30]
NADH dehydrogenase 1 beta subcomplex subunit 7 (NDUFB7) OT2CHQQ1 NDUB7_HUMAN Affects Response To Substance [12]
U11/U12 small nuclear ribonucleoprotein 25 kDa protein (SNRNP25) OT2MR6O2 SNR25_HUMAN Affects Response To Substance [12]
Biglycan (BGN) OT3AV6IF PGS1_HUMAN Affects Response To Substance [12]
Collagen alpha-1(VII) chain (COL7A1) OT3MIRZJ CO7A1_HUMAN Increases Response To Substance [71]
Solute carrier family 12 member 2 (SLC12A2) OT3ZJ3LH S12A2_HUMAN Decreases Response To Substance [71]
NADH dehydrogenase 1 beta subcomplex subunit 2, mitochondrial (NDUFB2) OT4717TF NDUB2_HUMAN Affects Response To Substance [12]
Sorcin (SRI) OT4R3EAC SORCN_HUMAN Decreases Response To Substance [72]
Ubiquitin-like protein ISG15 (ISG15) OT53QQ7N ISG15_HUMAN Affects Response To Substance [12]
MARVEL domain-containing protein 1 (MARVELD1) OT5CPOJE MALD1_HUMAN Increases Response To Substance [73]
Small ribosomal subunit protein uS15m (MRPS15) OT5HRAPP RT15_HUMAN Affects Response To Substance [12]
Signal recognition particle receptor subunit alpha (SRPRA) OT5NMYTY SRPRA_HUMAN Affects Response To Substance [12]
Annexin A1 (ANXA1) OT5OFDJC ANXA1_HUMAN Increases Response To Substance [71]
Collagen alpha-2(V) chain (COL5A2) OT5VOSQE CO5A2_HUMAN Decreases Response To Substance [15]
Transmembrane protein 135 (TMEM135) OT63ZT3X TM135_HUMAN Affects Response To Substance [12]
Farnesyl pyrophosphate synthase (FDPS) OT6CKWV5 FPPS_HUMAN Increases Response To Substance [30]
Ferritin heavy chain (FTH1) OT6IFS0O FRIH_HUMAN Decreases Response To Substance [30]
Claudin-3 (CLDN3) OT71MN9S CLD3_HUMAN Decreases Response To Substance [71]
Plasminogen activator inhibitor 2 (SERPINB2) OT72QLZB PAI2_HUMAN Affects Response To Substance [12]
DNA-binding protein RFX5 (RFX5) OT73KJ5P RFX5_HUMAN Decreases Response To Substance [30]
CD40 ligand (CD40LG) OT75Z6A6 CD40L_HUMAN Decreases Response To Substance [74]
Large ribosomal subunit protein P1 (RPLP1) OT7B0SIB RLA1_HUMAN Decreases Response To Substance [30]
Nucleolar and spindle-associated protein 1 (NUSAP1) OT85HIJ5 NUSAP_HUMAN Affects Response To Substance [12]
Mitotic checkpoint serine/threonine-protein kinase BUB1 beta (BUB1B) OT8KME51 BUB1B_HUMAN Affects Response To Substance [75]
Transcriptional repressor CTCF (CTCF) OT8ZB70U CTCF_HUMAN Decreases Response To Substance [30]
Neuron navigator 3 (NAV3) OT97M1TR NAV3_HUMAN Affects Response To Substance [12]
Solute carrier family 22 member 18 (SLC22A18) OT9C3KR4 S22AI_HUMAN Decreases Response To Substance [71]
Gamma-interferon-inducible lysosomal thiol reductase (IFI30) OT9DERT1 GILT_HUMAN Decreases Response To Substance [30]
FXYD domain-containing ion transport regulator 3 (FXYD3) OT9PPRHE FXYD3_HUMAN Increases Response To Substance [30]
Proteasome subunit beta type-6 (PSMB6) OT9VXPNW PSB6_HUMAN Affects Response To Substance [12]
High mobility group nucleosome-binding domain-containing protein 3 (HMGN3) OTA2TBWS HMGN3_HUMAN Affects Response To Substance [12]
Atypical chemokine receptor 3 (ACKR3) OTA6GA4F ACKR3_HUMAN Decreases Response To Substance [30]
Diphosphoinositol polyphosphate phosphohydrolase NUDT4B (NUDT4) OTA6ICI2 NUD4B_HUMAN Affects Response To Substance [12]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Increases Response To Substance [76]
Proteasome subunit alpha type-4 (PSMA4) OTAD2XXI PSA4_HUMAN Affects Response To Substance [12]
POM121 and ZP3 fusion protein (POMZP3) OTAH2JOK POZP3_HUMAN Affects Response To Substance [12]
Mediator of RNA polymerase II transcription subunit 4 (MED4) OTALFN4S MED4_HUMAN Affects Response To Substance [12]
snRNA-activating protein complex subunit 1 (SNAPC1) OTAPN1NI SNPC1_HUMAN Increases Response To Substance [71]
Collagen alpha-3(VI) chain (COL6A3) OTAS6R6I CO6A3_HUMAN Affects Response To Substance [12]
Desmoplakin (DSP) OTB2MOP8 DESP_HUMAN Affects Response To Substance [12]
Large ribosomal subunit protein mL40 (MRPL40) OTB2QZDY RM40_HUMAN Affects Response To Substance [12]
Large ribosomal subunit protein uL16 (RPL10) OTBHOZGC RL10_HUMAN Affects Response To Substance [12]
Probable ATP-dependent RNA helicase DDX23 (DDX23) OTBJHS8C DDX23_HUMAN Affects Response To Substance [12]
Coatomer subunit epsilon (COPE) OTBKHBT7 COPE_HUMAN Affects Response To Substance [12]
Protein FAM3C (FAM3C) OTBR6U9G FAM3C_HUMAN Affects Response To Substance [12]
Transmembrane protein 134 (TMEM134) OTBX9H9D TM134_HUMAN Affects Response To Substance [12]
Tight junction protein ZO-3 (TJP3) OTC1K8HC ZO3_HUMAN Decreases Response To Substance [71]
Cyclin-dependent kinase 4 inhibitor C (CDKN2C) OTCLOV90 CDN2C_HUMAN Affects Response To Substance [12]
Gamma-adducin (ADD3) OTDRSHAZ ADDG_HUMAN Affects Response To Substance [12]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A) OTDRV63V GA45A_HUMAN Decreases Response To Substance [30]
Superkiller complex protein 8 (SKIC8) OTDSQYDN SKI8_HUMAN Affects Response To Substance [12]
DNA-binding protein RFXANK (RFXANK) OTDX1026 RFXK_HUMAN Affects Response To Substance [12]
Transcription initiation factor TFIID subunit 1 (TAF1) OTDYS5G4 TAF1_HUMAN Affects Response To Substance [77]
EF-hand calcium-binding domain-containing protein 7 (EFCAB7) OTE0EG10 EFCB7_HUMAN Affects Response To Substance [12]
GTP cyclohydrolase 1 feedback regulatory protein (GCHFR) OTEOT8GI GFRP_HUMAN Decreases Response To Substance [71]
Tyrosine-protein phosphatase non-receptor type 13 (PTPN13) OTESFZSO PTN13_HUMAN Increases Response To Substance [71]
Rho GDP-dissociation inhibitor 1 (ARHGDIA) OTEXWJDO GDIR1_HUMAN Affects Response To Substance [78]
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha (PIK3C2A) OTFBU4GD P3C2A_HUMAN Affects Response To Substance [12]
Laminin subunit alpha-2 (LAMA2) OTFROQWE LAMA2_HUMAN Increases Response To Substance [15]
Cytotoxic granule associated RNA binding protein TIA1 (TIA1) OTGPN3P8 TIA1_HUMAN Affects Response To Substance [12]
Gasdermin-D (GSDMD) OTH39BKI GSDMD_HUMAN Affects Response To Substance [79]
Neurogenic locus notch homolog protein 1 (NOTCH1) OTI1WADQ NOTC1_HUMAN Decreases Response To Substance [80]
Interstitial collagenase (MMP1) OTI4I2V1 MMP1_HUMAN Affects Response To Substance [12]
G2/mitotic-specific cyclin-B2 (CCNB2) OTIEXTDK CCNB2_HUMAN Affects Response To Substance [12]
Polycystin-2 (PKD2) OTIXBU8H PKD2_HUMAN Increases Response To Substance [71]
G/T mismatch-specific thymine DNA glycosylase (TDG) OTJB0YIH TDG_HUMAN Affects Response To Substance [12]
E3 ubiquitin-protein ligase FANCL (FANCL) OTJC7QPQ FANCL_HUMAN Affects Response To Substance [12]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase epsilon-1 (PLCE1) OTJISZOX PLCE1_HUMAN Decreases Response To Substance [71]
Transmembrane protein 168 (TMEM168) OTJKZ6G9 TM168_HUMAN Affects Response To Substance [12]
Plakophilin-2 (PKP2) OTJOVF68 PKP2_HUMAN Decreases Response To Substance [71]
Tyrosine-protein kinase receptor UFO (AXL) OTKA2SUX UFO_HUMAN Increases Response To Substance [71]
NADH dehydrogenase 1 alpha subcomplex subunit 1 (NDUFA1) OTKBUQXP NDUA1_HUMAN Affects Response To Substance [12]
CCN family member 1 (CCN1) OTKJBEMD CCN1_HUMAN Increases Response To Substance [71]
Serine/threonine-protein kinase PLK2 (PLK2) OTKMJXJ8 PLK2_HUMAN Increases ADR [4]
Galectin-4 (LGALS4) OTKQCG0H LEG4_HUMAN Decreases Response To Substance [71]
Transcription factor E2F1 (E2F1) OTLKYBBC E2F1_HUMAN Increases Response To Substance [81]
Peptidyl-prolyl cis-trans isomerase B (PPIB) OTLPH6KN PPIB_HUMAN Affects Response To Substance [12]
Keratin, type II cytoskeletal 7 (KRT7) OTLT3JFN K2C7_HUMAN Increases Response To Substance [71]
Peroxiredoxin-2 (PRDX2) OTLWCY9T PRDX2_HUMAN Affects Response To Substance [12]
Hemicentin-1 (HMCN1) OTLZAS0P HMCN1_HUMAN Increases Response To Substance [15]
NADH dehydrogenase iron-sulfur protein 8, mitochondrial (NDUFS8) OTMEAWKO NDUS8_HUMAN Affects Response To Substance [12]
Probable dolichyl pyrophosphate Glc1Man9GlcNAc2 alpha-1,3-glucosyltransferase (ALG8) OTMFG2YY ALG8_HUMAN Affects Response To Substance [12]
Glutathione S-transferase Mu 5 (GSTM5) OTMMBFY8 GSTM5_HUMAN Decreases Response To Substance [30]
Unconventional myosin-Va (MYO5A) OTMWLP3E MYO5A_HUMAN Increases Response To Substance [71]
Integral membrane protein 2B (ITM2B) OTMXEPXB ITM2B_HUMAN Affects Response To Substance [12]
Succinate--CoA ligase subunit beta, mitochondrial (SUCLA2) OTMZD4PW SUCB1_HUMAN Affects Response To Substance [12]
Four and a half LIM domains protein 1 (FHL1) OTN535SU FHL1_HUMAN Increases Response To Substance [71]
Proto-oncogene serine/threonine-protein kinase mos (MOS) OTNMQPFJ MOS_HUMAN Increases ADR [4]
Nuclear factor NF-kappa-B p105 subunit (NFKB1) OTNRRD8I NFKB1_HUMAN Increases ADR [4]
Calcium-activated potassium channel subunit alpha-1 (KCNMA1) OTNYXOZO KCMA1_HUMAN Affects Response To Substance [12]
G-protein coupled receptor 35 (GPR35) OTO23NRK GPR35_HUMAN Decreases Response To Substance [71]
Receptor tyrosine-protein kinase erbB-2 (ERBB2) OTOAUNCK ERBB2_HUMAN Decreases Response To Substance [82]
Arginine/serine-rich protein 1 (RSRP1) OTOAZLCL RSRP1_HUMAN Affects Response To Substance [12]
Malectin (MLEC) OTOPGRF5 MLEC_HUMAN Affects Response To Substance [12]
Interleukin-13 receptor subunit alpha-2 (IL13RA2) OTPC2G0X I13R2_HUMAN Affects Response To Substance [12]
DNA dC->dU-editing enzyme APOBEC-3C (APOBEC3C) OTPL0AI1 ABC3C_HUMAN Affects Response To Substance [12]
Prostaglandin E synthase 3 (PTGES3) OTPPQWI0 TEBP_HUMAN Affects Response To Substance [12]
Large ribosomal subunit protein uL23 (RPL23A) OTPYLCCX RL23A_HUMAN Decreases Response To Substance [30]
Aldo-keto reductase family 1 member C2 (AKR1C2) OTQ2XMO3 AK1C2_HUMAN Increases Response To Substance [30]
Glutamine--fructose-6-phosphate aminotransferase 1 (GFPT1) OTQBDO45 GFPT1_HUMAN Decreases Response To Substance [71]
MAPK/MAK/MRK overlapping kinase (MOK) OTQK7M9V MOK_HUMAN Affects Response To Substance [12]
Keratin, type I cytoskeletal 23 (KRT23) OTQW6UAG K1C23_HUMAN Increases Response To Substance [15]
Fibroblast growth factor 5 (FGF5) OTQXGHBY FGF5_HUMAN Affects Response To Substance [12]
Solute carrier family 22 member 3 (SLC22A3) OTQYGVXX S22A3_HUMAN Affects Response To Substance [12]
Nuclear body protein SP140 (SP140) OTQZHFMT SP140_HUMAN Affects Response To Substance [12]
Transforming growth factor-beta-induced protein ig-h3 (TGFBI) OTR443C5 BGH3_HUMAN Decreases Response To Substance [15]
E3 ubiquitin-protein ligase CHFR (CHFR) OTRAD2TT CHFR_HUMAN Decreases Response To Substance [83]
Large ribosomal subunit protein mL63 (MRPL57) OTRB659E RT63_HUMAN Affects Response To Substance [12]
Protein CREG1 (CREG1) OTRHJ8HK CREG1_HUMAN Affects Response To Substance [12]
Acidic leucine-rich nuclear phosphoprotein 32 family member A (ANP32A) OTRHPFO2 AN32A_HUMAN Affects Response To Substance [12]
Retinol-binding protein 1 (RBP1) OTRP1MFC RET1_HUMAN Increases Response To Substance [71]
Receptor tyrosine-protein kinase erbB-3 (ERBB3) OTRSST0A ERBB3_HUMAN Decreases Response To Substance [71]
Aldo-keto reductase family 1 member B1 (AKR1B1) OTRX72TH ALDR_HUMAN Increases Response To Substance [71]
Arrestin-C (ARR3) OTRZ00CH ARRC_HUMAN Decreases Response To Substance [30]
MHC class I polypeptide-related sequence B (MICB) OTS2DVDW MICB_HUMAN Increases Response To Substance [71]
Latent-transforming growth factor beta-binding protein 2 (LTBP2) OTS88GSD LTBP2_HUMAN Affects Response To Substance [12]
Calcium/calmodulin-dependent protein kinase type II subunit beta (CAMK2B) OTS9YK3E KCC2B_HUMAN Affects Response To Substance [12]
Lumican (LUM) OTSRC874 LUM_HUMAN Decreases Response To Substance [15]
Rhotekin (RTKN) OTSS8XR6 RTKN_HUMAN Decreases Response To Substance [84]
Plasminogen activator inhibitor 1 (SERPINE1) OTT0MPQ3 PAI1_HUMAN Affects Response To Substance [12]
Collagen alpha-1(III) chain (COL3A1) OTT1EMLM CO3A1_HUMAN Decreases Response To Substance [15]
Lipopolysaccharide-induced tumor necrosis factor-alpha factor (LITAF) OTT5JX1F LITAF_HUMAN Affects Response To Substance [12]
Amyloid beta precursor like protein 2 (APLP2) OTTFE53M APLP2_HUMAN Affects Response To Substance [12]
Collagen alpha-1(XV) chain (COL15A1) OTTFKK18 COFA1_HUMAN Decreases Response To Substance [15]
Keratin, type I cytoskeletal 13 (KRT13) OTTYSKGX K1C13_HUMAN Decreases Response To Substance [30]
Annexin A4 (ANXA4) OTUCRYXL ANXA4_HUMAN Decreases Response To Substance [85]
N-acetylgalactosaminyltransferase 7 (GALNT7) OTUJSCAO GALT7_HUMAN Affects Response To Substance [12]
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit DAD1 (DAD1) OTUUNQBT DAD1_HUMAN Increases ADR [4]
Mitochondrial Rho GTPase 2 (RHOT2) OTV8WT2L MIRO2_HUMAN Affects Response To Substance [12]
Matrilin-2 (MATN2) OTVDR68G MATN2_HUMAN Decreases Response To Substance [15]
Integrin beta-1-binding protein 1 (ITGB1BP1) OTVQFNGS ITBP1_HUMAN Affects Response To Substance [12]
U2 small nuclear ribonucleoprotein A' (SNRPA1) OTWJZFAP RU2A_HUMAN Affects Response To Substance [12]
CASP8 and FADD-like apoptosis regulator (CFLAR) OTX14BAS CFLAR_HUMAN Decreases Response To Substance [86]
Transmembrane protein 59 (TMEM59) OTX4EKES TMM59_HUMAN Affects Response To Substance [12]
Nucleotide triphosphate diphosphatase NUDT15 (NUDT15) OTX8SZOT NUD15_HUMAN Affects Response To Substance [12]
Metallothionein-1E (MT1E) OTXJKU4Y MT1E_HUMAN Increases Response To Substance [30]
NADH dehydrogenase 1 alpha subcomplex subunit 3 (NDUFA3) OTXL10N9 NDUA3_HUMAN Affects Response To Substance [12]
Mitotic spindle assembly checkpoint protein MAD2A (MAD2L1) OTXNGZCG MD2L1_HUMAN Affects Response To Substance [75]
Neuroendocrine protein 7B2 (SCG5) OTXSJMT1 7B2_HUMAN Affects Response To Substance [12]
Peripheral myelin protein 22 (PMP22) OTXWYWCZ PMP22_HUMAN Decreases Response To Substance [30]
Collagen alpha-2(I) chain (COL1A2) OTY7G382 CO1A2_HUMAN Increases Response To Substance [15]
Serine/threonine-protein phosphatase PP1-beta catalytic subunit (PPP1CB) OTYFTYFR PP1B_HUMAN Affects Response To Substance [12]
Ferritin light chain (FTL) OTYQA8A6 FRIL_HUMAN Decreases Response To Substance [30]
Proteasome subunit beta type-1 (PSMB1) OTYRFBAH PSB1_HUMAN Affects Response To Substance [12]
ADP-ribosylation factor 3 (ARF3) OTYYQX85 ARF3_HUMAN Affects Response To Substance [12]
Mitochondrial import inner membrane translocase subunit Tim13 (TIMM13) OTYZQJD3 TIM13_HUMAN Affects Response To Substance [12]
Tissue factor pathway inhibitor 2 (TFPI2) OTZCRWOR TFPI2_HUMAN Affects Response To Substance [12]
Insulin-induced gene 1 protein (INSIG1) OTZF5X1D INSI1_HUMAN Affects Response To Substance [12]
C-X-C motif chemokine 5 (CXCL5) OTZOUPCA CXCL5_HUMAN Affects Response To Substance [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 338 DOT(s)

References

1 ClinicalTrials.gov (NCT02824575) Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
2 Paclitaxel FDA Label
3 Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
4 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
5 Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines. J Gastroenterol. 2006 Feb;41(2):140-50.
6 Effects of paclitaxel on proliferation and apoptosis in human acute myeloid leukemia HL-60 cells. Acta Pharmacol Sin. 2004 Mar;25(3):378-84.
7 Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol Oncol. 2005 Jul;98(1):45-53. doi: 10.1016/j.ygyno.2005.04.010.
8 Changes of gene expression of thymidine phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 5'-deoxy-5-fluorouridine, paclitaxel and its combination in human gastric cancer xenografts. Anticancer Res. 2008 May-Jun;28(3A):1593-602.
9 Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels. Cell Death Differ. 2000 Jun;7(6):574-86. doi: 10.1038/sj.cdd.4400688.
10 Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
11 2-Methoxyestradiol and paclitaxel have similar effects on the cell cycle and induction of apoptosis in prostate cancer cells. Cancer Lett. 2006 Jan 8;231(1):49-64. doi: 10.1016/j.canlet.2005.01.018.
12 Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
13 Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells. Prostate. 2005 Jan 1;62(1):61-8. doi: 10.1002/pros.20117.
14 Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer. 2004 Sep 10;111(4):617-26. doi: 10.1002/ijc.20289.
15 Microarray-based detection and expression analysis of extracellular matrix proteins in drug?resistant ovarian cancer cell lines. Oncol Rep. 2014 Nov;32(5):1981-90. doi: 10.3892/or.2014.3468. Epub 2014 Sep 9.
16 Uroporphyrinogen decarboxylase is a radiosensitizing target for head and neck cancer. Sci Transl Med. 2011 Jan 26;3(67):67ra7. doi: 10.1126/scitranslmed.3001922.
17 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
18 Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6125-32.
19 Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther. 2001 Sep;298(3):1236-42.
20 Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
21 Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
22 Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds. Eur J Med Chem. 2015 Mar 6;92:723-31.
23 Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res. 2008 Jul 1;68(13):5380-9.
24 MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9.
25 Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther. 2005 Aug;4(8):815-8.
26 Overexpression of microRNA-24 increases the sensitivity to paclitaxel in drug-resistant breast carcinoma cell lines via targeting ABCB9. Oncol Lett. 2016 Nov;12(5):3905-3911.
27 Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67.
28 FaDu cell characteristics induced by multidrug resistance. Oncol Rep. 2011 Nov;26(5):1189-95. doi: 10.3892/or.2011.1418. Epub 2011 Aug 10.
29 Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. Head Neck. 2011 Jul;33(7):959-68. doi: 10.1002/hed.21559. Epub 2010 Aug 24.
30 cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance. Breast Cancer Res Treat. 2006 Mar;96(1):17-39. doi: 10.1007/s10549-005-9026-6. Epub 2005 Dec 2.
31 [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel]. Zhonghua Fu Chan Ke Za Zhi. 2007 Jun;42(6):412-6.
32 Marked regression of liver metastasis by combined therapy of ultrasound-mediated NF kappaB-decoy transfer and transportal injection of paclitaxel, in mouse. Int J Cancer. 2008 Apr 1;122(7):1645-56. doi: 10.1002/ijc.23280.
33 The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol. 2009 Nov;175(5):2226-34.
34 Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther. 2004 Jan;3(1):71-84.
35 CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos. 2002 Jul;30(7):795-804.
36 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
37 Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res. 2001 Jan 15;61(2):759-63.
38 Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009 Aug 21;138(4):645-659. doi: 10.1016/j.cell.2009.06.034. Epub 2009 Aug 13.
39 Orlistat Displays Antitumor Activity and Enhances the Efficacy of Paclitaxel in Human Hepatoma Hep3B Cells. Chem Res Toxicol. 2019 Feb 18;32(2):255-264. doi: 10.1021/acs.chemrestox.8b00269. Epub 2019 Jan 22.
40 Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells. Cancer Biol Ther. 2005 Jul;4(7):716-9. doi: 10.4161/cbt.4.7.1782. Epub 2005 Jul 2.
41 Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling. Mutat Res. 2007 Jun 1;619(1-2):16-29. doi: 10.1016/j.mrfmmm.2006.12.007. Epub 2007 Feb 8.
42 Norcantharidin combined with paclitaxel induces endoplasmic reticulum stress mediated apoptotic effect in prostate cancer cells by targeting SIRT7 expression. Environ Toxicol. 2021 Nov;36(11):2206-2216. doi: 10.1002/tox.23334. Epub 2021 Jul 16.
43 CWF-145, a novel synthetic quinolone derivative exerts potent antimitotic activity against human prostate cancer: Rapamycin enhances antimitotic drug-induced apoptosis through the inhibition of Akt/mTOR pathway. Chem Biol Interact. 2016 Dec 25;260:1-12. doi: 10.1016/j.cbi.2016.10.014. Epub 2016 Oct 18.
44 Effect of trans-resveratrol on signal transduction pathways involved in paclitaxel-induced apoptosis in human neuroblastoma SH-SY5Y cells. Neurochem Int. 2003 Apr;42(5):419-29. doi: 10.1016/s0197-0186(02)00132-8.
45 Protein kinase Cdelta-dependent induction of manganese superoxide dismutase gene expression by microtubule-active anticancer drugs. J Biol Chem. 1998 Dec 18;273(51):34639-45. doi: 10.1074/jbc.273.51.34639.
46 pRb2/p130 decreases sensitivity to apoptosis induced by camptothecin and doxorubicin but not by taxol. Clin Cancer Res. 2004 Dec 1;10(23):8085-93. doi: 10.1158/1078-0432.CCR-04-0996.
47 Activator protein 2alpha status determines the chemosensitivity of cancer cells: implications in cancer chemotherapy. Cancer Res. 2005 Oct 1;65(19):8628-34. doi: 10.1158/0008-5472.CAN-05-1059.
48 Genotoxic, cytotoxic, and apoptotic effects of Hypogymnia physodes (L.) Nyl. on breast cancer cells. Environ Toxicol. 2014 May;29(7):804-13. doi: 10.1002/tox.21809. Epub 2012 Aug 21.
49 ERK activation and subsequent RB phosphorylation are important determinants of the sensitivity to paclitaxel in lung adenocarcinoma cells. Int J Oncol. 2004 Jun;24(6):1499-504.
50 Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. J Biol Chem. 1999 Mar 19;274(12):8208-16. doi: 10.1074/jbc.274.12.8208.
51 Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004 Feb 7;25(3):94-102. doi: 10.1016/j.cyto.2003.10.004.
52 Combination of all-trans retinoic acid and paclitaxel-induced differentiation and apoptosis in human glioblastoma U87MG xenografts in nude mice. Cancer. 2008 Feb 1;112(3):596-607. doi: 10.1002/cncr.23223.
53 Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst. 2012 Mar 21;104(6):476-87. doi: 10.1093/jnci/djs002. Epub 2012 Feb 1.
54 Cacalol, a natural sesquiterpene, induces apoptosis in breast cancer cells by modulating Akt-SREBP-FAS signaling pathway. Breast Cancer Res Treat. 2011 Jul;128(1):57-68. doi: 10.1007/s10549-010-1076-8. Epub 2010 Jul 28.
55 Development and applications of a real-time quantitative RT-PCR method (QRT-PCR) for BRCA1 mRNA. Clin Biochem. 2005 Jan;38(1):50-7. doi: 10.1016/j.clinbiochem.2004.09.012.
56 Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
57 Involvement of Asp-Glu-Val-Asp-directed, caspase-mediated mitogen-activated protein kinase kinase 1 Cleavage, c-Jun N-terminal kinase activation, and subsequent Bcl-2 phosphorylation for paclitaxel-induced apoptosis in HL-60 cells. Mol Pharmacol. 2001 Feb;59(2):254-62. doi: 10.1124/mol.59.2.254.
58 Enhancement of esculetin on Taxol-induced apoptosis in human hepatoma HepG2 cells. Toxicol Appl Pharmacol. 2006 Jan 1;210(1-2):55-62. doi: 10.1016/j.taap.2005.06.020. Epub 2005 Jul 26.
59 Thymidine phosphorylase suppresses apoptosis induced by microtubule-interfering agents. Biochem Pharmacol. 2005 Jul 1;70(1):13-21. doi: 10.1016/j.bcp.2005.04.017.
60 Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther. 2001 Dec;1(2):141-9.
61 Interaction of cisplatin, paclitaxel and adriamycin with the tumor suppressor PTEN. Anticancer Drugs. 2001 Nov;12(10):797-800. doi: 10.1097/00001813-200111000-00002.
62 Association of cell cycle arrest with anticancer drug-induced epithelial-mesenchymal transition in alveolar epithelial cells. Toxicology. 2019 Aug 1;424:152231. doi: 10.1016/j.tox.2019.06.002. Epub 2019 Jun 4.
63 Combination of all-trans retinoic acid and taxol regressed glioblastoma T98G xenografts in nude mice. Apoptosis. 2007 Nov;12(11):2077-87. doi: 10.1007/s10495-007-0116-2. Epub 2007 Aug 16.
64 Olesoxime prevents microtubule-targeting drug neurotoxicity: selective preservation of EB comets in differentiated neuronal cells. Biochem Pharmacol. 2010 Sep 15;80(6):884-94. doi: 10.1016/j.bcp.2010.04.018. Epub 2010 Apr 22.
65 Amyloid beta protein-related death-inducing protein induces G2/M arrest: Implications for neurodegeneration in Alzheimer's disease. J Neurosci Res. 2007 Aug 1;85(10):2262-71. doi: 10.1002/jnr.21351.
66 Validation of a genotoxicity test based on p53R2 gene expression in human lymphoblastoid cells. Mutat Res. 2011 Sep 18;724(1-2):76-85. doi: 10.1016/j.mrgentox.2011.06.003. Epub 2011 Jun 17.
67 3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer. Int J Clin Oncol. 2001 Jun;6(3):128-31. doi: 10.1007/pl00012094.
68 Administration of PUMA adenovirus increases the sensitivity of esophageal cancer cells to anticancer drugs. Cancer Biol Ther. 2006 Apr;5(4):380-5. doi: 10.4161/cbt.5.4.2477. Epub 2006 Apr 4.
69 MM-TRAG (MGC4175), a novel intracellular mitochondrial protein, is associated with the taxol- and doxorubicin-resistant phenotype in human cancer cell lines. Gene. 2004 Sep 29;340(1):53-9. doi: 10.1016/j.gene.2004.06.013.
70 Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol. 2008 Mar;45(5):1470-6. doi: 10.1016/j.molimm.2007.08.013. Epub 2007 Oct 24.
71 Gene expression analysis using human cancer xenografts to identify novel predictive marker genes for the efficacy of 5-fluorouracil-based drugs. Cancer Sci. 2006 Jun;97(6):510-22. doi: 10.1111/j.1349-7006.2006.00204.x.
72 [Correlation of sorcin overexpression to multidrug resistance of human gastric cancer cell line SGC7901]. Ai Zheng. 2008 Apr;27(4):337-42.
73 Inhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cells. Oncotarget. 2016 Aug 9;7(32):52392-52403.
74 CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways. BMC Cancer. 2006 Mar 18;6:75. doi: 10.1186/1471-2407-6-75.
75 Mitotic checkpoint genes, hsMAD2 and BubR1, in oesophageal squamous cancer cells and their association with 5-fluorouracil and cisplatin-based radiochemotherapy. Clin Oncol (R Coll Radiol). 2008 Oct;20(8):639-46. doi: 10.1016/j.clon.2008.06.010. Epub 2008 Aug 8.
76 CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes. Anticancer Res. 2010 Dec;30(12):4791-8.
77 MIAT shuttled by tumor-secreted exosomes promotes paclitaxel resistance in esophageal cancer cells by activating the TAF1/SREBF1 axis. J Biochem Mol Toxicol. 2023 Aug;37(8):e23380. doi: 10.1002/jbt.23380. Epub 2023 May 3.
78 Reduced expression of Rho guanine nucleotide dissociation inhibitor-alpha modulates the cytotoxic effect of busulfan in HEK293 cells. Anticancer Drugs. 2007 Mar;18(3):333-40. doi: 10.1097/CAD.0b013e328011fd7f.
79 The role of Caspase-1/GSDMD-mediated pyroptosis in Taxol-induced cell death and a Taxol-resistant phenotype in nasopharyngeal carcinoma regulated by autophagy. Cell Biol Toxicol. 2020 Oct;36(5):437-457. doi: 10.1007/s10565-020-09514-8. Epub 2020 Jan 28.
80 Inhibition of the notch signaling pathway overcomes resistance of cervical cancer cells to paclitaxel through retardation of the epithelial-mesenchymal transition process. Environ Toxicol. 2021 Sep;36(9):1758-1764. doi: 10.1002/tox.23296. Epub 2021 May 28.
81 E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents. Cancer Res. 2006 Jul 15;66(14):7253-60. doi: 10.1158/0008-5472.CAN-05-3725.
82 Pculin02H, a curcumin derivative, inhibits proliferation and clinical drug resistance of HER2-overexpressing cancer cells. Chem Biol Interact. 2015 Jun 25;235:17-26. doi: 10.1016/j.cbi.2015.04.005. Epub 2015 Apr 10.
83 Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes. Int J Oncol. 2007 Oct;31(4):713-20.
84 Rho/Rhotekin-mediated NF-kappaB activation confers resistance to apoptosis. Oncogene. 2004 Nov 18;23(54):8731-42. doi: 10.1038/sj.onc.1208106.
85 Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw. 2011 Jun 1;9(6):681-9. doi: 10.6004/jnccn.2011.0056.
86 Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel. Anticancer Res. 2005 May-Jun;25(3c):2367-79.